Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186


Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG.

J Clin Oncol. 2013 Jul 1;31(19):2396-403. doi: 10.1200/JCO.2012.43.7103. Epub 2013 May 28.


Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG.

J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.


Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U.

J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.


Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.

Adam V, Wauters I, Vansteenkiste J.

Expert Opin Biol Ther. 2014 Mar;14(3):365-76. doi: 10.1517/14712598.2014.880421. Epub 2014 Jan 24. Review.


Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.

Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF.

J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.


Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N.

Lancet Oncol. 2016 Jun;17(6):822-35. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.


MAGE A3 antigen-specific cancer immunotherapeutic.

Peled N, Oton AB, Hirsch FR, Bunn P.

Immunotherapy. 2009 Jan;1(1):19-25. doi: 10.2217/1750743X.1.1.19. Review.


Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.

Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S.

Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1650-5. doi: 10.1073/pnas.0707140104. Epub 2008 Jan 23.


MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.

Tyagi P, Mirakhur B.

Clin Lung Cancer. 2009 Sep;10(5):371-4. doi: 10.3816/CLC.2009.n.052.


Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study.

Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B.

Eur J Cardiothorac Surg. 2004 Jan;25(1):131-4.


Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.

Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S.

J Immunol. 2009 Oct 1;183(7):4800-8. doi: 10.4049/jimmunol.0900903. Epub 2009 Sep 4.


Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.

Grah JJ, Katalinic D, Juretic A, Santek F, Samarzija M.

Tumori. 2014 Jan-Feb;100(1):60-8. doi: 10.1700/1430.15817.


A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW.

Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.


Prediction of response to anticancer immunotherapy using gene signatures.

Wang E, Bedognetti D, Marincola FM.

J Clin Oncol. 2013 Jul 1;31(19):2369-71. doi: 10.1200/JCO.2013.49.2157. Epub 2013 May 28. No abstract available.


Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.

Ruiz R, Hunis B, Raez LE.

Curr Oncol Rep. 2014 Sep;16(9):400. doi: 10.1007/s11912-014-0400-6. Review.


Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.

Liu X, Li J, Liu Y, Ding J, Tong Z, Liu Y, Zhou Y, Liu Y.

Cell Immunol. 2016 Feb;300:46-53. doi: 10.1016/j.cellimm.2015.12.003. Epub 2015 Dec 14.


What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?

Reck M.

Ann Oncol. 2012 Sep;23 Suppl 8:viii28-34. doi: 10.1093/annonc/mds260. Review.


[Molecular biology of lung cancer series].

Hiret S, Senellart H, Bennouna J.

Rev Mal Respir. 2010 Oct;27(8):954-8. doi: 10.1016/j.rmr.2010.08.002. Review. French.


Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.

Ratto GB, Costa R, Maineri P, Alloisio A, Piras MT, D'Agostino A, Tripodi G, Rivabella L, Dozin B, Bruzzi P, Melioli G.

Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):1005-16.


Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR.

J Clin Oncol. 2008 Nov 1;26(31):5043-51. doi: 10.1200/JCO.2008.16.4855. Epub 2008 Sep 22.

Items per page

Supplemental Content

Support Center